AIkido Pharma Adds Inventor Dr. Neil H. Bander, M.D. to Scientific Advisory Board
New Board Member Brings Expertise in Oncology Research
Released On: 02/02/2021
Views: 1547
Aikido Pharma Secures Early Interest in Next Generation Radiotherapy
Currently in Human Phase 2 Trials for Treatment of Prostate Cancer
Released On: 01/02/2021
Views: 1674
AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements
Released On: 22/01/2021
Views: 746
AIkido Pharma Inc. Executes Licensing Agreement for Psilocybin for Cancer Applications
Released On: 06/01/2021
Views: 679
AIkido Pharma Announces Publication of Artificial Intelligence-Machine Learning Sponsored Research Program for Pancreatic Cancer
Released On: 09/12/2020
Views: 642
AIkido Pharma Inc. Announces Results of 2020 Annual Stockholder Meeting
Released On: 20/11/2020
Views: 631
AIkido Pharma Inc. Announces Publication of Favorable Peer Reviewed Study of Newly Licensed Antiviral Compounds
Released On: 13/11/2020
Views: 638
AIkido Pharma Inc. Provides Update on Its Next-Generation Chemotherapeutic Treatment DHA-dFdC
Released On: 28/10/2020
Views: 654
AIkido Pharma Announces Update On Its Use Of Artificial Intelligence
Released On: 18/09/2020
Views: 609
AIkido Pharma Inc. Announces Participation at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 2020 (Virtual Conference)
Released On: 11/09/2020
Views: 613
AIkido Pharma Announces Peer-Reviewed Publication of Positive Results from Study of Antiviral Compounds Licensed from University of Maryland, Baltimore
Released On: 11/09/2020
Views: 630
AIkido Pharma Sponsors Survival Study of University of Kentucky Anticancer Drug G4-1 in Exchange for Exclusive Option to License
Released On: 18/08/2020
Views: 580
Map
Aikido Pharma
Get DirectionsAikido Pharma
-
One Rockefeller Plaza
New York, New York 10020
United States - (212) 745-1373
